Pan-RAS inhibitor development for KRAS-mutated cancers — the mutation-agnostic small-molecule targeting of multiple KRAS, HRAS, and NRAS isoforms representing the fastest-growing drug class in the global RAS-acting agents market — creates the most commercially expansive market segment, with the RAS-Acting Agents Market reflecting pan-RAS inhibition as the next-generation growth...